Zoetis Inc. (NYSE:ZTS) Receives Consensus Rating of “Buy” from Brokerages

Zoetis Inc. (NYSE:ZTS) has been given an average recommendation of “Buy” by the seven research firms that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $211.75.

Several equities research analysts recently weighed in on ZTS shares. The Goldman Sachs Group reduced their price target on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Piper Sandler reissued an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. HSBC lowered their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Barclays lowered their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the transaction, the executive vice president now owns 15,723 shares in the company, valued at $2,725,267.59. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 2,209 shares of company stock valued at $371,293. 0.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zoetis

Hedge funds have recently bought and sold shares of the stock. Hohimer Wealth Management LLC lifted its holdings in Zoetis by 1.2% in the 4th quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock valued at $866,000 after purchasing an additional 52 shares in the last quarter. Forum Financial Management LP increased its stake in shares of Zoetis by 0.8% in the 4th quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after acquiring an additional 56 shares during the last quarter. Angeles Wealth Management LLC increased its stake in shares of Zoetis by 3.5% in the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after acquiring an additional 56 shares during the last quarter. Prossimo Advisors LLC increased its stake in shares of Zoetis by 1.7% in the 4th quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after acquiring an additional 57 shares during the last quarter. Finally, River Street Advisors LLC increased its stake in shares of Zoetis by 3.4% in the 4th quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after acquiring an additional 58 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 2.1 %

Zoetis stock opened at $164.92 on Thursday. The stock has a market cap of $75.25 billion, a P/E ratio of 31.78, a PEG ratio of 2.57 and a beta of 0.86. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. Zoetis has a 1 year low of $144.80 and a 1 year high of $201.92. The firm’s 50 day moving average price is $167.64 and its 200-day moving average price is $178.93.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter in the previous year, the business posted $1.31 earnings per share. Zoetis’s quarterly revenue was up 9.5% on a year-over-year basis. On average, equities analysts predict that Zoetis will post 5.77 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.